Market Assessment, Market Events and Forecast Respiratory US/EU5 2021 Report

In 2019, sales of branded biologics for respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Market Events and Forecast | Respiratory | US/EU5 | 2021

Related Market Assessment Reports

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) 2023

Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)